APA Not on Board With ‘Physician Associate’; COVID’s Immune-Mediated Depression

The American Psychiatric Association (APA) released a statement against the American Academy of PAs’ decision to rebrand their profession by changing the title of physician assistant to physician associate; the APA said it would increase patient confusion.

Natural early birds were less likely to experience depressive symptoms compared with night owls. (Molecular Psychiatry)

Another symptom COVID long-haulers may face: immune-mediated depression. (Forbes)

Obsessive-compulsive disorder may be under-represented as a primary diagnosis, according to an analysis of commercial healthcare claims presented at the Going Digital: Behavioral Health Tech conference.

Not surprisingly, more than half of transgender or gender minority adolescents between the ages of 13 and 17 said they use substances as a way to cope with stress. (PLOS One)

A psychiatrist from New York City was lampooned after sharing fantasies of shooting white people in the head during a talk at Yale University, although she said she was only using “provocation as a tool for real engagement.” (New York Times)

A pooled analysis of three clinical trials found that 42 mg of lumateperone (Caplyta) for schizophrenia was both safe and tolerable, showing a similar metabolic profile compared with placebo, Intra-Cellular Therapies announced.

Maine is facing a psychiatrist shortage, due to its aging population and not enough young people entering the field. (Bangor Daily News)

  • Kristen Monaco is a staff writer, focusing on endocrinology, psychiatry, and dermatology news. Based out of the New York City office, she’s worked at the company for nearly five years.

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button

Ad Block Detected

Welcome to Mediexpose, Please support our journalism by allowing ads. With support from readers like you, we can continue to deliver the best. You can support us free by simply allowing ads.